{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Inozyme Pharma, Inc."},"Symbol":{"label":"Symbol","value":"INZY"},"Address":{"label":"Address","value":"321 SUMMER STREET,SUITE 400, BOSTON, Massachusetts, 02210, United States"},"Phone":{"label":"Phone","value":"+1 857 330-4340"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies."},"CompanyUrl":{"label":"Company Url","value":"https://www.inozyme.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Douglas A. Treco","title":"Chairman & Chief Executive Officer"},{"name":"Kurt C. Gunter","title":"Chief Medical Officer & Senior Vice President"},{"name":"Matthew J. Winton","title":"Chief Operating Officer & Senior Vice President"},{"name":"Soo-Jin Kim","title":"Chief Technical Operations Officer & Senior VP"},{"name":"Yves Sabbagh","title":"Chief Scientific Officer & Senior Vice President"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}